Overview

Eligibility

Design Details

Arms & Interventions

Outcome Measures

Trial Sites

Source: NCT06654336

Recruiting

RATIONAL: Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

Interventional

Phase 2

Juravinski Cancer Centre

Sponsor: Ontario Clinical Oncology Group (OCOG)

Last Updated: March 13, 2026
Notice- Information is sourced from public registries and may not reflect real-time changes at the local site.

The goal of this study is to determine whether the addition of Androgen Deprivation Therapy (ADT) utilizing the study drug ELIGARD® to Recurrence- Directed Therapy (RDT) improves progression-free survival (PFS) compared to RDT alone in patients with early radio-recurrent oligo-metastatic castrate / hormone sensitive prostate cancer (romCSPC). Participants will be assessed at standard of care clinic visits every 3 months. The follow-up period is 36 months.

Show Detailed Description

Treatment Category

Other Non-Drugs, Other Drugs

Required Mutations

None

Trial Started

March 30, 2026

Last Updated by Sponsor

March 13, 2026

Estimated Completion

April 1, 2031

Contact Study

Name:Lisa Rudd-Scott, RN BScN

Email:ruddl@mcmaster.ca

Phone:905-527-2299

Name:Daryl Solomon

Email:solomd5@mcmaster.ca

Phone:905-527-2299

Eligibility

Inclusion Criteria

1. Previous biopsy-proven localized prostate adenocarcinoma (without predominant features of sarcomatoid, small cell or neuroendocrine carcinoma) treated with definitive or salvage radiotherapy ≥ 2 years or more before enrollment.

2. Recurrent Oligo-metastatic CSPC, M0 on conventional imaging (bone scan and CT scan of chest/abdomen/pelvis) with ≤ 5 metastases cumulative on all imaging, including MRI and PSMA-PET.

Note: Patients with conventional imaging M1 oligometastatic CSPC, who have no more than 5 metastatic sites in all imaging modalities including MRI and PSMA-PET, will be accepted for study enrollment.

3. All sites of recurrent disease must be amenable to treatment with radiotherapy or surgery in the judgment of the investigator.

4. Biochemical recurrent prostate cancer with ONE of the following PSA recurrence definitions:

1. After definitive radiotherapy (prostate in situ), with PSA ≥ nadir + 2ng/ml;

2. After prostatectomy and adjuvant/salvage radiotherapy, with PSA ≥ nadir + 0.2ng/ml.

Exclusion Criteria

1. Age < 18.

2. ECOG Performance Status ≥3.

3. PSA ≥ 20 ng/ml.

4. Treatment with ADT within 2 years from study enrollment or treatment with any androgen receptor axis within 6 months from study enrollment.

5. Prior treatment with chemotherapy for prostate cancer or bilateral orchiectomy. Note: prior chemotherapy for a different type of cancer is allowed if the patient has been continuously disease-free for > 3 years.

6. Intracranial or intrathecal metastasis.

7. Spinal cord compression, or spinal intramedullary metastasis.

8. Prior malignancy (except non metastatic, non- melanomatous skin cancer) unless disease free for > 3 years.

9. Bilateral hip prosthesis, treated earlier with definitive prostate radiotherapy, who have evidence of local disease recurrence within the prostate and no option for salvage treatment with brachytherapy or surgery.

10. Previous documented hypersensitivity to ELIGARD® or other GnRH agonist analogs of components of such preparations.

Do you think this trial is incorrectly appearing?

Design Details

AllocationRandomized

Intervention ModelParallel Assignment

MaskingNone (Open Label)

Number to Enroll162

Arms & Interventions

Arms

Interventions

Type: Experimental

Description: Local, regional or distant oligometastatic RDT in addition to treatment with ADT for 12 months in the form of ELIGARD®.

Interventions:

Recurrence-directed therapy (RDT)
ELIGARD 22.5mg

Outcome Measures

Primary Outcome Measures

Composite progression free survivalTime from randomization to the occurrence of composite PFS event occurring up to the 36 month follow-up.

Biochemical, radiological or clinical progression [composite PFS (cPFS) event]

Secondary Outcome Measures

Disease progressionTime from date of randomization, until the date of progression or death occurring up to the 36 month follow-up.

Disease progression: time to biochemical progression (bPFS) (proportion of bPFS events); Disease progression: proportion of conventional-imaging based progression (rPFS) (proportion of rPFS events); Disease progression: proportion with eugonadal progression (egPFS)

Time to initiation of tertiary therapy;Time of initial therapy to 36 month follow-up.

Any non-protocol treatment given for prostate cancer after protocol-specified intervention.

Proportion of patients that develop castrate-resistant prostate cancer (CRPC)During the 36 month follow-up.

Proportion of patients that develop castrate-resistant prostate cancer (CRPC)

Overall survival.During the 36 month follow-up.

Overall survival.

Rate of early and late Grade 3 or higher GU and GI toxicity.At 3, 6, 15 and 36 months.

The rate of early and late Grade 3 or higher GU and GI toxicity will be assessed at baseline, 3, 6, 15 and 36 months. The CTCAEv.5.0 (> Grade 3, GI and GU) toxicity rates will be reported.

Quality of life assessed by EORTC QLQ C30Completed by the study participant at scheduled follow-up visits (Months 3, 6, 15 and 36).

Study participant reported quality of life utilizing the following measurement EORTC QLQ C30

Quality of life assessed by EORTC QLQ PR25 questionnaireCompleted by the study participant at scheduled follow-up visits (Months 3, 6, 15 and 36).

Quality of life assessed by EORTC QLQ PRT20 questionnaireCompleted by the study participant at scheduled follow-up visits (Months 3, 6, 15 and 36).

Bookmark trial

Share Trial

Download Trial

Do you think this trial is incorrectly appearing?

Report Trial

Download Trial

Trial Sites

This study has 3 trial sites

Juravinski Cancer Centre

Hamilton, Ontario, CA

Name:Theos Tsakiridis, Dr.

Email:tsakirid@hhsc.ca

Phone:001-905-525-9140

Recruiting

Hamilton, Ontario, CA

Juravinski Cancer Centre

Not yet recruiting

Ottawa, Ontario, K1H8L6 CA

The Ottawa Hospital Regional Cancer Centre

Recruiting

Montreal, Quebec, H1T2M4 CA

Jewish General Hospital

Loading Maps...